The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Open accessAbstract
BACKGROUND: Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, a twice-daily sustained-release formulation followed in 1996, and, in August 2003, a once-daily extended-release formulation was introduced. On the 15th anniversary of its introduction, we undertook a review of the background/history, mechanism of action, formulations, and clinical profile of bupropion. DATA SOURCES: Major efficacy trials and other reports were obtained and reviewed from MEDLINE searches, review of abstracts from professional meetings, and the bupropion SR manufacturer's databases. Searches of English-language articles were conducted from June 2003 through August 2004. No time limit was specified in the searches, which were conducted using the search terms bupropion, bupropion SR, and bupropion XL. DATA SYNTHESIS: Bupropion inhibits the re-uptake of norepinephrine and dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. Bupropion is an effective antidepressant with efficacy comparable to selective serotonin reuptake inhibitors and other antidepressants. It is well tolerated in short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, and dizziness are the most common adverse events. Seizure and allergic reactions are medically important adverse events associated with bupropion and are reported rarely. Among all the newer antidepressants in the United States, bupropion appears to have among the lowest incidence of sexual dysfunction, weight gain, and somnolence. Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents. CONCLUSION: Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“However, in a study in which bupropion was combined with a nicotine patch, there was an increased incidence of treatment-emergent hypertension in the combination group compared to the placebo group or the bupropion alone group.(46) Blood pressure should be monitored in patients receiving bupropion in combination with…”
BackgroundSelf-citationA Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,261
Self-citationBupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citationFava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Self-citationStahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
Self-citationTashkin, D., Kanner, R., Bailey, W., Buist, S., Anderson, P., Nides, M., Gonzales, D., Dozier, G., Patel, M., & Jamerson, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04724-3 · Cited by 413
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Self-citationBupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity
CONNERS, C. K., CASAT, C. D., GUALTIERI, C. T., WELLER, E., READER, M., REISS, A., WELLER, R. A., KHAYRALLAH, M., & ASCHER, J. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00018 · Cited by 342
Cited by
The dopamine motive system: implications for drug and food addiction
Volkow, N. D., Wise, R. A., & Baler, R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.130 · Cited by 939
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Jefferson, J. W., Pradko, J. F., & Muir, K. T. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.011 · Cited by 408
Self-citationNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Self-citationBupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Papakostas, G. I., Nutt, D. J., Hallett, L. A., Tucker, V. L., Krishen, A., & Fava, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.015 · Cited by 334
Self-citationKaster, T. S., Daskalakis, Z. J., Noda, Y., Knyahnytska, Y., Downar, J., Rajji, T. K., Levkovitz, Y., Zangen, A., Butters, M. A., Mulsant, B. H., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0121-x · Cited by 174
Jha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T. L., Mayes, T. L., & Trivedi, M. H. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.005 · Cited by 79
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
A Review of Modern Antidepressants Effects on Neurocognitive Function
Biringer, E., Rongve, A., & Lund, A. (2009) · Current Psychiatry Reviews · doi:10.2174/157340009788971137 · Cited by 73
“Bupropion inhibits synaptic re-uptake of norepinephrine and dopamine without any significant direct effects on serotonin neurotransmission [109].”
BackgroundHewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V, Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089602 · Cited by 57
Biological basis for the co-morbidity between smoking and mood disorders
Mineur, Y. S., & Picciotto, M. R. (2009) · Journal of Dual Diagnosis · doi:10.1080/15504260902869964 · Cited by 51
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Kobayashi, Y., Koshino, Bahk, W.-M., & Sakai (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s48158 · Cited by 6
Rujescu, D., Röttig, S., & Krause, T. J. (2020) · NeuroPsychopharmacotherapy · doi:10.1007/978-3-319-56015-1_83-1 · Cited by 2
Metadata
- Authors
- Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-06-15
- Volume
- 7
- Issue
- 3
- Pages
- 106-13
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- OpenAlex
- W2082205780
- Cited by
- 258
- References
- 60
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.